title: In response to "Selective serotonin reuptake inhibitors--a new modality for the treatment of lymphoma/leukaemia?" by C. Schuster, et al. [Biochem. Pharmacol. 74 (9) 2007 1424-1435].
authors.forename: John
authors.initials: J
authors.lastname: Gordon
authors.forename: Nicholas
authors.initials: N
authors.lastname: Barnes
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Meredith
authors.forename: Mark
authors.initials: M
authors.lastname: Drayson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D045744:Cell Line, Tumor; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D005473:Fluoxetine; D019253:Proto-Oncogene Proteins c-bcl-2; D017367:Selective Serotonin Reuptake Inhibitors